Novartis Internal Investigation: Up To 10,000 Side Effect Reports Delayed
This article was originally published in PharmAsia News
There has been a delay in roughly 10,000 reports regarding side effects of Novartis products delivered by sales reps to the safety assessment department, according to a statement by the company on June 9.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.